TGFB1 and pemphigus foliaceus: Monoclonal antibodies targeting TGF-β1 [58], the inhibition of integrin protein αvβ6 [59], which is an activator of TGF-β1, and the inhibition of the type 1 receptor of TGF-β1 [60] have proven to be effective in alleviating PF.